DSM Sinochem Pharmaceuticals has initiated patent litigation against Sinopharm Weiqida Pharmaceutical
Producers of enzymatic antibiotics, statins and anti-fungals DSM Sinochem Pharmaceuticals, has filed lawsuits for patent infringement against Chinese producers of anti-infective drugs, Sinopharm Weiqida Pharmaceutical.
DSM's subsidiaries, DSM Sinochem Pharmaceuticals Netherlands and DSM Pharmaceuticals India both filed two lawsuits against Sinopharm Weiqida Pharmaceutical Weiqida for patent infringement regarding amoxicillin trihydrate.
The Eurpoean patent dispute was filed in in the District Court of The Hague, Afdeling Handel, Netherlands, while an Indian patent dispute was addressed in the High Court of Delhi at New Delhi. These patents claim the low free water content of amoxicillin trihydrate and describe the processes for manufacture.
DSM seeks an injunction to prevent the manufacture, use, importation and sale of Weiqida’s amoxicillin active pharmaceutical ingredient in the Netherlands and India, as well as any drug product that utilises the active pharmaceutical ingredient.
Karl Rotthier, CEO at DSP said: “DSP will rigorously defend its IP assets worldwide as it continues to invest in its innovative R and D programs directed to enzymatic, sustainable antimicrobials and statins.”
Weiqida has not yet made a statement.